BTC$62,769.00-0.20%
ETH$1,795.23+0.98%
USDT$0.9988-0.02%
BNB$570.12+0.34%
USDC$0.9999+0.01%
XRP$1.07-0.75%
SOL$75.21-1.19%
TRX$0.3248-0.76%
FIGR_HELOC$1.03+1.91%
HYPE$63.84-1.72%
DOGE$0.0721-0.02%
USDS$0.9999+0.02%
RAIN$0.0142-1.58%
LEO$9.55+0.30%
ZEC$507.33-1.11%
WBT$55.10+0.04%
BTC$62,769.00-0.20%
ETH$1,795.23+0.98%
USDT$0.9988-0.02%
BNB$570.12+0.34%
USDC$0.9999+0.01%
XRP$1.07-0.75%
SOL$75.21-1.19%
TRX$0.3248-0.76%
FIGR_HELOC$1.03+1.91%
HYPE$63.84-1.72%
DOGE$0.0721-0.02%
USDS$0.9999+0.02%
RAIN$0.0142-1.58%
LEO$9.55+0.30%
ZEC$507.33-1.11%
WBT$55.10+0.04%
Abbott stock fell more than 7% in premarket trading after the company missed on Q4 revenue and gave a weaker Q1 2026 outlook, even with earnings at $1.50 per share.
Exact Sciences surged more than 17% premarket after Abbott announced a $23 billion buyout, adding Cologuard and Oncotype DX to its diagnostics lineup.
Abbott Laboratories reported a strong start to 2025 with significant growth in sales and EPS, exceeding market expectations.
Abbott Laboratories reported a strong third-quarter performance in 2024.
Abbott Laboratories (NYSE: ABT) reported sales of $10.4 billion in the second quarter of 2024, reflecting a 4.0% increase from the same period last year.
Abbott has reported a strong start to the year with sales reaching $10.0 billion in Q1, driven by a 10.8 percent increase in organic sales growth.
Abbott Laboratories announces Q4 results with $10.24 billion in revenue and an EPS of $1.19.